![]() |
||||||||||||
|
|
||||||||||||
|
DEVELOPMENT OF MONOCLONAL ANTIBODIES Before beginning with the work, the specific characteristics of the antigen against which monoclonal antibodies are to be developed should be discussed with the customer. This will be helpful to verify whether i.e., specially designated screening methods for the specific mAk are necessary or already in place. The antigens are provided by the customer. Peptides with less than 30 amino acids must possess an additional C- or N-terminal Cystein residue for coupling to a carrier protein. This must be considered in the course of the synthesis. For antigens with more than 30 amino acids, 2 mg are needed for the immunisations and 1 mg for the screening; for peptides with less than 30 amino acids, 5 mg peptide is needed for the coupling to a carrier protein und 1mg for the screening. Custom monoclonal antibodies (mab) generation at UNICUS usually takes 5-6 months and is divided into 3 phases: Work package 1: Immunisation (5-6 weeks)
Work package 2: Cell Fusion, Selection, Screening (app. 1 month)
Work package 3: Cloning, Re-cloning, Testing, Characterisation (app. 2 months)
Following co-ordination measures to this effect, the customer can, in the meantime, receive 1 ml of cell culture supernatant for each selected culture after primary screening, cloning and re-cloning for specific tests. Billing: The billing takes place in two instalments. If stoppage of the work should prove necessary, only those services provided up to that point will in fact be billed. Prices: |
|
|
*plus VAT and transport costs. The price for more than 5 antigens is negotiable. Payment conditions: 30 days in full from the bill date Possible additional services: Cloning of more than 8 primary cultures: 50.00 € / Culture Free of charge:
All results of a project become the property of the customer after payment. The UNICUS Karlsburg OHG is obligated to refrain from either using the results of this development work itself or transmitting these results to any third parties. Strict confidentiality is considered part and parcel of the agreement. |